Solvotrin Therapeutics was incorporated and established in 2009 after the discovery of a platform of salicylate and niacin pro-drugs, which are backed by a family of granted and pending patents.
Based in Cork Ireland, we are a rapidly growing medicine development company. After beginning as a spin out from Trinity College in 2010, we began the development of a new form of Aspirin. Aspirin is one of the most prescribed drugs in the world and is used to prevent clotting, heart attacks, stroke and death in patients with cardiovascular disease. However, up to 75% of patients using Aspirin have detectable levels of gastric bleeding. Dr. Gilmer, VP Research and Development, discovered that he could deactivate Aspirin to protect the stomach and intestine lining, allowing it be activated later by enzymes naturally present in the blood, thereby liberating active aspirin only when it is in the bloodstream. In this way, the drug maintains its therapeutic qualities, without the damaging gastrointestinal side effects. This continues to be a key research project for the Solvotrin team.
In 2013 we began a second development track focused on iron. Iron is one of the most common mineral deficiencies in the World, effecting people in both developed and developing countries in equal measure. Active Iron is clinically proven to be better absorbed than the gold standard ferrous sulfate. The microencapsulated formulation results in less iron-related oxidative stress and damage in gut cells than ferrous sulfate. Active Iron was brought to market in 2016 and now consists of a portfolio of three products, Active Iron Base, Active Iron for Women and Active Iron for Men. There are a further three products scheduled for launch in 2019.
Building on the success of Active Iron in 2017 we began the development of a range of Food For Special Medical Purpose (FSMP). We are aiming to deliver a range of oral iron combination products for patients with disease-related malnutrition. These patients require oral iron products that are better absorbed and better tolerated than those currently available.
The third development track for the company is in the area of Pro Drugs. Since 2015 we have been investigating the opportunity to utilize pro drug technology in the area’s of inflammatory skin disease and oncology.